Corcept’s Lifyorli Combination Shows Early Promise in Platinum-Resistant Ovarian Cancer
Positive Phase 2 data suggest Lifyorli plus chemotherapy and bevacizumab may offer meaningful benefit in hard-to-treat platinum-resistant ovarian cancer.
Positive Phase 2 data suggest Lifyorli plus chemotherapy and bevacizumab may offer meaningful benefit in hard-to-treat platinum-resistant ovarian cancer.
Rina-S shows significant PFS and OS gains in platinum-resistant ovarian cancer, challenging Corcept’s Lifyorli position.
Corcept stock looks overpriced despite strong drug sales; analysts warn expectations are too high and risks could drag shares lower.
Corcept will resubmit its NDA for relacorilant to treat Cushing’s syndrome after positive FDA feedback.
UBS upgraded CORT to Buy, raised target to $72 on strong Lifyorli cancer drug outlook and steady Korlym sales. Upside ~60–70%.
The FDA has approved Corcept's relacorilant (Lifyorli) in combination with nab-paclitaxel for platinum-resistant ovarian, fallopian tube, or peritoneal cancer, showing improved survival by several months.